Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)

Assessment of the relevance of a new medical imaging test, FAPI PET, which could detect progression or relapse earlier than other tests currently available. Ultimately, it could enable early forms of pancreatic cancer to be detected and used for screening. In addition to the usual examinations prescribed, FAPI PET scans will be repeated at several points in the treatment process. All study patients must first have been included in the Homing cohort (NCT 04363983, APHP promotion). Clinical characteristics, judgement criteria and results of biological or imaging examinations carried out as part of this cohort will be shared. Patient follow-up and participation in the study ends when conventional imaging (CT and MRI) shows disease progression, relapse or death.

NCT Number	NCT06659705
Lead Sponsor	Institut Curie
Conditions	Pancreatic Ductal Adenocarcinoma (PDAC)
Enrollment	35 participants
Start Date	2025-12-02
Primary Completion	2029-08-04 (estimated)
Study Completion	2030-08-08 (estimated)
Updated on ClinicalTrials.gov	2026-04-15